Back to search results

AIManage for Diabetes, Obesity, and Medication Side Effects

This study is testing a new tool called AIManage, which uses artificial intelligence (AI) to help manage incretin mimetic medications (IMM). These medications are used for conditions like diabetes and obesity, and can have side effects. AIManage aims to give personalized guidance to patients on managing side effects and help doctors adjust medication doses. The study is currently in its first phase, gathering information to improve the tool. You might be able to join if you are an adult (18 years or older) who is currently taking an IMM or has taken one in the last six months, and can speak English or Spanish. The study will look at how useful, easy to use, and challenging people find AIManage.

Study design
This is an interventional study with a planned enrollment of 16 participants. It is currently in Phase 1, which involves formative data collection.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be assessed on perceived usefulness, usability, and use challenges at Day 1 (60 minutes).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07546357

AIManage Using an AI-driven CDS and Chatbot

Not Yet Recruiting
NAAges 18+Interventional
NYU Langone Health
~16 participants
Updated 2026-04-22 on ClinicalTrials.gov
What's tested:AIManage

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of Patients who Complete Qualitative Measure - Perceived Usefulness
Measured over Day 1 (60 minutes)
+3 more outcomes measured

Conditions

Diabetes
Obesity
Medication Side Effects

Explore related trials

Diabetes MellitusObesity

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Elizabeth Stevens, PhD, MPH · PRINCIPAL_INVESTIGATOR · NYU Langone Health

Who to contact

Elizabeth Stevens, PhD, MPH
[email protected]
646-501-2558
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Primary or bariatric care provider (MD/DO, NP) practicing at the participating NYULH clinics,
Provide care to at least 5 patients prescribed an IMM.
(Phase 1) Currently taking an IMM or have taken an IMM in the past 6 months;
Fluency in English or Spanish;
Be willing to send/receive text messages; and
Be \> 18 years of age.

What this trial measures

  • Percentage of Patients who Complete Qualitative Measure - Perceived UsefulnessDay 1 (60 minutes)

    In Phase 1, qualitative data regarding perceived usefulness will be collected.

  • Percentage of Patients who Complete Qualitative Measure - Perceived UsabilityDay 1 (60 minutes)

    In Phase 1, qualitative data regarding perceived usability will be collected.

  • Percentage of Patients who Complete Qualitative Measure - Perceived Use ChallengesDay 1 (60 minutes)

    In Phase 1, qualitative data regarding perceived use challenges will be collected.

  • Percentage of Patients who Complete Qualitative Measure - Perceived ValueDay 1 (60 minutes)

    In Phase 1, qualitative data regarding perceived value will be collected.